Outcomes of Hematopoietic Stem Cell Transplantation with Different Stem Cell Sources in Children with Malignant and Non-malignant Hematologic Diseases.
- Author:
Kyu Tae NOH
1
;
Jae Ho YOO
;
Young Seok LEE
;
Young Ho LEE
;
Hyuk Chan KWON
;
Jae Seok KIM
;
Hyo Jin KIM
Author Information
1. Hematopoietic Stem Cell Transplantation Program, Dong-A Cancer Center, Dong-A University College of Medicine, Busan, Korea. yhlee1@mail.donga.ac.kr
- Publication Type:Original Article
- Keywords:
Hematopoietic stem cell transplantation;
Stem cell source;
Hematologic disease
- MeSH:
Bacteremia;
Blood Platelets;
Bone Marrow Transplantation;
Child*;
Cord Blood Stem Cell Transplantation;
Disease-Free Survival;
Follow-Up Studies;
Graft vs Host Disease;
Hematologic Diseases*;
Hematopoietic Stem Cell Transplantation*;
Hematopoietic Stem Cells*;
Humans;
Incidence;
Neutrophils;
Peripheral Blood Stem Cell Transplantation;
Recurrence;
Retrospective Studies;
Stem Cells*;
Survival Rate;
Tissue Donors;
Transplants
- From:Korean Journal of Pediatric Hematology-Oncology
2002;9(1):54-63
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We compared the clinical outcomes of allogeneic bone marrow transplantation (BM), peripheral blood stem cell transplantation (PB) and cord blood stem cell transplantation (CB) in children with malignant and non-malignant diseases. METHODS: We retrospectively analysed the engraftment speed, episodes of infection, acute graft versus host disease (GVHD), and survival rate in 27 children who underwent hematopoietic stem cell transplantation (HSCT) at Dong-A Cancer Center from August 1998 to July 2001. RESULTS: HSCT were done with BM in 16 patients, CB in 6 and PB in 5. The neutrophil and platelet engraftment were achieved at 13.27+/-4.10, 24.58+/-9.41 days in BM, 12.00+/-1.09, 15.88+/-4.42 days in PB, and 39.00+/-15.68, 76.50+/-37.01 days in CB (P=0.001, P=0.001). There were 17 episodes of bacteremia and 10 episodes of viral infections without any significant differences between stem cell sources. There were 8 cases (7 in BM, 1 in CB) of acute GVHD, 4 cases (2 in BM, 2 in CB) of graft failure and 3 cases of relapse (1 in BM, 2 in CB) after HSCT. The duration of median follow-up was 14.34+/-8.32 months in BM, 11.43+/-10.03 months in PB, and 16.56+/-13.76 months in CB. The overall and event free survival rate were 81.5% and 63.0%, respectively. CONCLUSION: There were no significant differences in episodes of infection between the types of HSCT. Although there were HLA mismatched donors for CB, the incidence of acute GVHD was lower, and graft failure or relapse rate was higher than BM.
